MVision AI obtains a new CE mark: Ultimate segmentation service now with lymph nodes

Less than a year after the CE marking of MVision Segmentation Service 1.1, our team has obtained another one: The state-of-the-art solution is now also available with lymph nodes. With the ability to contour lymph nodes, we enter an era where AI algorithms actually help clinicians in every contouring step of treatment planning.

Our algorithms accurately follow guidelines with lymph nodes making it efficient for clinicians to select the lymph levels to be treated and combine them in their treatment planning system. After reviewing, clinicians can simply apply a margin to create the planning target volume”, explains MVision AI CPO Jarkko Niemelä.

There are approximately 500-600 lymph nodes in a human body. Until now, clinicians have drawn lymph nodes with all lymph levels by hand. Going back and forth drawing and checking dozens of glands in one region, this method can take hours to complete. The risk for inter-observer variation is also high. 

MVision AI Segmentation Service 1.2 produces accurate auto-segmentation of lymph nodes for the pelvis, breast as well as head and neck in minutes. The system is trained to rigorously follow official guidelines. For the male pelvis, there are also two different versions available: pivotal and RTOG. A full list of guidelines in use can be found here

Lymph Nodes with Segmentation Service 1.2

The test use of the update has shown tremendous results. A recent study also supports its impact particularly in terms of decreased inter-observer variation with increased efficiency.

The lymph node release indeed marks a new era, and I am extremely proud of our team for making it happen especially in the middle of the current circumstances“, concludes founder & CEO Mahmudul Hasan


Would you like to see the new update in action? Let us know and we’ll get back to you.

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

13.12.2024

Saad Ullah Akram Appointed as CEO of MVision AI

Helsinki, Finland – MVision AI, a leading provider of AI-powered solutions for radiation therapy treatment planning, announces the appointment of Saad Ullah Akram as its new Chief Executive Officer. Known for its commitment to streamlining workflows and enhancing treatment quality in cancer care, MVision AI is embarking on an exciting…

Press Releases

20.11.2024

MVision AI Ranked Among the Top 10 in Deloitte Technology Fast 50 Finland for 2024

Helsinki, Finland, 20 November 2024 – MVision AI, a leading innovator in AI-driven solutions for oncology, is proud to announce its recognition among the top ten companies in the Deloitte Technology Fast 50 Finland 2024 ranking. This prestigious award acknowledges MVision AI's rapid growth and its mission-driven advancements in making…

Press Releases

7.11.2024

Safe and Ethical AI in Radiation Oncology: Regulations and MVision’s Compliance

Technology is evolving, and the same applies to Radiation Oncology. New ways and new tools require new rules. Artificial intelligence (AI)  brings tremendous potential, so the world has to learn how to get the best of it, safely.  Al systems identified as high-risk have to comply with strict requirements, including…

Articles